Genomadix
The company is seeing its CYP2C19 test adopted broadly as it prepares to submit a new application to the FDA for an assay targeting neurodegenerative disease.
Genomadix Gets FDA 510(k) Clearance for PCR System, CYP2C19 Test
Canada's Genomadix, formerly known as Spartan Bioscience, expects to now commercialize the system and test in the US to guide therapy decisions.